Pharmacokinetics and pharmacodynamics of famotidine in children with gastroduodenal ulcers.
We treated 14 boys, six with gastric ulcers and eight with duodenal ulcers, to determine famotidine pharmacokinetics and its inhibition of gastric acid secretion (pharmacodynamics). Famotidine (1 mg/kg/day) was administered either intravenously or orally at a dose of 0.5 mg/kg twice a day (maximum: 40 mg/day). Blood samples were collected from all subjects and the intragastric pH monitored in eight. Pharmacokinetic parameters were calculated assuming a one-compartment model. Volume of distribution, elimination half-life, and area under the serum concentration-time curve were 1.52 +/- 0.37 l/kg, 2.29 +/- 0.38 h, and 1.14 +/- 0.32 ng.h/ml, respectively. The mean oral bioavailability of famotidine was 50.6%. Both intravenously and orally administered famotidine neutralized gastric acidity during sleep but failed to continuously maintain the intragastric pH > 5.0. All subjects' ulcers healed within 8 weeks. There were no side effects noted during famotidine treatment. Twice daily administration of 0.5 mg/kg famotidine for 8 weeks appears to be a tolerated and effective treatment of children with gastroduodenal ulcers.
Nagita
A
A
Department of Pediatrics, Osaka Medical College, Japan.
Manago
M
M
Aoki
S
S
Mino
M
M
Suzuki
K
K
Ashida
K
K
D000284:Administration, Oral; D000293:Adolescent; D001682:Biological Availability; D002648:Child; D015738:Famotidine / Q000097:blood / Q000493:pharmacokinetics* / Q000494:pharmacology*; D005744:Gastric Acid / Q000378:metabolism; D005753:Gastric Mucosa / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007275:Injections, Intravenous; D008297:Male; D010437:Peptic Ulcer / Q000188:drug therapy* / Q000378:metabolism* / Q000503:physiopathology
D015738:Famotidine